



For Immediate Release
April 14, 2016

Contacts: Steven Grossman 1-301-539-9660
Ladd Wiley 202-887-4083

House Subcommittee FY 17 FDA Appropriation Improves on President's Request, But Higher Funding Still Needed

Silver Spring, MD---The Alliance for a Stronger FDA, which advocates for Food and Drug Administration (FDA) funding, today commented on the House Appropriations Subcommittee bill that would provide the FDA with \$2.754 billion in budget authority appropriations for fiscal year 2017. The amount is \$33 million above the FY 16 appropriation for FDA and \$18 million above the President's request for FDA funding for FY 17.

The Alliance said the Subcommittee bill "is heading in the right direction" in increasing FDA's budget but is "in stark contrast to the steady investments over the past years in FDA's critical public health work, including more than a \$100 million increase in the prior fiscal year."

"The Alliance for a Stronger FDA is encouraged that the House proposal for FDA funding exceeds the Administration's meager request," said Cynthia Bens, Alliance President and Vice President, Public Policy at the Alliance for Aging Research. "Nonetheless, the House mark fails to acknowledge FDA's rapidly expanding role in food and drug safety and innovative medical product development."

She added: "FDA is already responsible for products that represent about 20% of American consumer spending and is being asked to do more each year. In addition, Congress has pending legislation that will further increase the responsibilities of FDA as soon as FY 17 (starts October 1, 2016). To continue its record of achievement, the agency needs Congress to provide increased resources."

"We are concerned that the House subcommittee mark will require FDA to choose among competing public health priorities, which could put the health and safety of the American people at risk," said Troy Zimmerman, Alliance Vice President and Vice President for Government Relations at the National Kidney Foundation.

He added: "This subcommittee mark provides modest investment in FDA's core functions, even while additional funding is needed for food safety, precision medicine, drug compounding oversight, antibiotics development and other initiatives."

The Alliance for a Stronger FDA is comprised of more than 180 consumer, patient and research advocacy organizations, health professions societies, trade associations, companies and individuals. More information about the Alliance can be found at www.StrengthenFDA.org.

Attachment: Analysis of the House Subcommittee proposal for FY 17 funding for FDA by Center and Compared to Prior Years and the President's FY 17 request.



**FY 17 Budget Authority Appropriations for FDA
Compared to FY 14-16
(as of April 13, 2016, **subject to further revision**)
Not all numbers add due to rounding**

Function Budget authority only, by center; no user fees	FY 14 Final	FY15 Final	FY 16 Final	FY 17 President's Request 2/9/16	FY 17 House SC Mark-up 4/13/16
Food	\$ 883 million	\$ 903 million	\$ 987 million	\$ 1.013 billion	\$ 1.023 billion
Human Drugs	\$ 466 million	\$ 482 million	\$ 492 million	\$ 492 million	\$ 496 million
Biologics	\$ 211 million	\$ 211 million	\$ 215 million	\$ 215 million	\$ 216 million
Animal Drugs/Feed	\$ 141 million	\$ 148 million	\$ 159 million	\$ 162 million	\$ 161 million
Devices & Radiological Health	\$ 321 million	\$ 321 million	\$ 323 million	\$ 326 million	\$ 326 million
Natl. Ctr. For Toxicological Research	\$ 62 million	\$ 63 million	\$ 63 million	\$ 60 million	\$ 63 million
HQ, Officer. of Commissioner & Other	\$ 172 million	\$ 175 million	\$ 183 million	\$ 178 million	\$ 183 million
Rent & Facilities Cost	\$ 294 million	\$ 285 million	\$ 298 million	\$ 285 million	\$ 285 million
SUBTOTAL, Salaries & Expenses	\$2.550 billion	\$2.588 billion	\$ 2.721 billion	\$ 2.731 billion	\$2.754 billion (with rounding)
Building and Facilities Repair	\$ 9 million	\$ 9 million	\$ 9 million	\$ 12 million	\$ 12 million
Supplementals	-----	-----	-----	*	**
All BA appropriations Total (no user fees)	\$2.559 billion	\$ 2.597 billion	\$ 2.730 billion	\$ 2.743 billion	\$2.766 billion

* The Administration has proposed \$75 million for FDA in the cancer “moonshot” initiative and an unspecified amount for activities related to vaccines for the Zika virus. They are not embedded in the chart because they require authorizing legislation for FY 17 (cancer) or reprogramming or emergency supplemental legislation for FY 16 or 17 (Zika).

** Includes \$10 million in no-year money for Zika and Ebola activities